Abstract
Background
Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access.
Methods
A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability.
Results
We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant.
Conclusions
The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Johns Hopkins Bloomberg School of Public Health, Department of Environmental Health Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000000121719311); Johns Hopkins School of Medicine, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000000121719311)
2 University of Wisconsin-Madison, Department of Population Health Sciences, School of Medicine and Public Health and the Nelson Institute for Environmental Studies, Madison, USA (GRID:grid.14003.36) (ISNI:0000000121673675)
3 Johns Hopkins School of Medicine, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000000121719311)
4 Johns Hopkins School of Medicine, Department of Oncology (Urologic Oncology), Baltimore, USA (GRID:grid.21107.35) (ISNI:0000000121719311)




